請輸入關鍵字:

熱門搜尋:

Philip Morris International Announces U.S. Food and Drug Administration Authorization For Sale of IQOS in the United States

日期: 2019年5月6日 上午9:44

NEW YORK--()--The U.S. Food and Drug Administration (FDA) today confirmed that IQOS, Philip Morris International’s electrically heated tobacco system, is appropriate for the protection of public health and has authorized it for sale in the United States. FDA’s decision follows its comprehensive assessment of PMI’s premarket tobacco product applications (PMTAs) filed with the Agency in 2017.

Unlike cigarettes, the IQOS system heats — but does not burn — tobacco. It is the first electrically heated tobacco product to qualify for sale in the U.S. pursuant to the 2009 law that empowers FDA to regulate tobacco products, including through oversight of innovative products.

Commenting on the FDA’s announcement, André Calantzopoulos, PMI’s Chief Executive Officer, said:

“The FDA’s decision to authorize IQOS in the U.S. is an important step forward for the approximately 40 million American men and women who smoke. Some will quit. Most won’t, and for them IQOS offers a smoke-free alternative to continued smoking. In just two years, 7.3 million people around the world have abandoned cigarettes and switched completely to IQOS. Today’s decision by FDA makes this opportunity available to American adult smokers. All of us at PMI are determined to replace cigarettes with smoke-free alternatives that combine sophisticated technology and intensive scientific validation. FDA’s announcement is a historic milestone.”

He added, “The order sets out clear commercialization guidelines, including marketing requirements, that maximize the opportunity for adults to switch from cigarettes, while minimizing unintended use. We fully support this objective. FDA has set a high standard and we look forward to working with them to implement the order so that IQOS is reaching the right audience—current adult smokers.

PMI will bring IQOS to the U.S. market through an exclusive license with Altria Group, Inc., whose subsidiary Philip Morris USA has the market expertise and infrastructure to ensure a successful launch. PM USA is ready to deploy its initial lead market plans for IQOS.

PMI submitted a comprehensive body of scientific evidence in support of the PMTAs and of the parallel applications for IQOS as a “Modified Risk Tobacco Product”, which FDA continues to review.

Note to Editor

PMP SA submitted PMTA applications for IQOS and three HeatStick variants: Marlboro HeatSticks, Marlboro Smooth Menthol HeatSticks; and Marlboro Fresh Menthol HeatSticks.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2019, PMI estimates that approximately 7.3 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, which is currently available for sale in 47 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.

 

Philip Morris International Announces U.S. Food and Drug Administration Authorization For Sale of IQOS in the United States

Contacts

Corey Henry
Philip Morris International Media Office
T. +1 (202) 679 7296
E. corey.henry@pmi.com

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至 content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載APP 下載財華財經APP,把握投資先機
更多精彩内容,請點擊: 財華網(https://www.finet.hk/) 財華智庫網(https://www.finet.com.cn) 現代電視FINTV(http://www.fintv.hk)

視頻

快訊

17:34
香港於2025年第四季錄得465億元國際收支盈餘
17:31
香港二月份整體消費物價同比上升1.7%
17:18
香港中華煤氣(00003.HK)年度股東應佔溢利微降0.42%至56.88億港元 末期息23港仙
17:09
信基沙溪(03603.HK)料年度股東應佔淨虧損不少於2200萬至不多於3200萬元​
16:58
德琪醫藥-B(06996.HK)2025年虧損收窄至2.39億元
16:37
【盈喜】申萬宏源香港(00218.HK)料年度扭虧為盈 溢利1.1億至1.3億港元
16:36
章魚動力​完成近5000萬美元首輪融資
16:25
歌爾股份:目前暫未涉及MicroLED產品領域
16:20
【異動股】港股跌幅榜前十,大唐西市(00620.HK)跌42.74%,超人智能(08176.HK)跌30.86%
16:20
【異動股】港股漲幅榜前十,德萊建業(01546.HK)漲41.15%,智中國際(06063.HK)漲38.30%